CN114008041A - 整合应激反应路径的调节剂 - Google Patents

整合应激反应路径的调节剂 Download PDF

Info

Publication number
CN114008041A
CN114008041A CN202080046012.1A CN202080046012A CN114008041A CN 114008041 A CN114008041 A CN 114008041A CN 202080046012 A CN202080046012 A CN 202080046012A CN 114008041 A CN114008041 A CN 114008041A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
oxadiazol
acceptable salt
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080046012.1A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·布朗
I·D·雷布尔
Y·鲁德哈德
M·沙巴
D·S·沃尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evertec International Co ltd
Original Assignee
Evertec International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evertec International Co ltd filed Critical Evertec International Co ltd
Publication of CN114008041A publication Critical patent/CN114008041A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080046012.1A 2019-04-23 2020-04-22 整合应激反应路径的调节剂 Pending CN114008041A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19170502.9 2019-04-23
EP19170502 2019-04-23
PCT/EP2020/061148 WO2020216764A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
CN114008041A true CN114008041A (zh) 2022-02-01

Family

ID=66248567

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080046012.1A Pending CN114008041A (zh) 2019-04-23 2020-04-22 整合应激反应路径的调节剂

Country Status (12)

Country Link
US (1) US20220213078A1 (https=)
EP (1) EP3959210A1 (https=)
JP (1) JP7588089B2 (https=)
CN (1) CN114008041A (https=)
AU (1) AU2020262153B2 (https=)
BR (1) BR112021020106A2 (https=)
CA (1) CA3137212A1 (https=)
EA (1) EA202192900A1 (https=)
IL (1) IL287378B2 (https=)
MX (1) MX2021012904A (https=)
SG (1) SG11202111362SA (https=)
WO (1) WO2020216764A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109736A1 (zh) * 2022-11-21 2024-05-30 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其合成方法和用途
US12612392B2 (en) 2022-11-21 2026-04-28 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical compositions containing same, synthesis method therefor and use thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111757739A (zh) 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 整合应激反应路径抑制剂
AU2019282253A1 (en) 2018-06-05 2020-11-26 Altos Labs, Inc. Inhibitors of integrated stress response pathway
WO2020252207A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
CN115190813B (zh) 2020-03-11 2024-10-15 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
EP4232153A1 (en) 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway
RS66455B1 (sr) 2020-10-22 2025-02-28 Evotec Int Gmbh Modulatori puta integrisanog odgovora na stres
EP4232447A1 (en) 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209460A (zh) * 2013-03-14 2015-12-30 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
WO2019046779A1 (en) * 2017-09-01 2019-03-07 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
CN109563071A (zh) * 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 作为atf4途径抑制剂的化学化合物
CN109641853A (zh) * 2016-05-05 2019-04-16 卡里科生命科学有限责任公司 整合应激通路的调节剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
KR20190015492A (ko) 2016-06-08 2019-02-13 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학적 화합물
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
BR112020000122A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças
CA3071024A1 (en) 2017-08-09 2019-02-14 Denali Therapeutics Inc. Compounds, compositions and methods
WO2019090074A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
AU2018358157B2 (en) 2017-11-02 2023-03-09 Abbvie Inc. Modulators of the integrated stress pathway
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
WO2019090090A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019090088A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
CA3080808A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
JP2021501781A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
CN111757739A (zh) 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 整合应激反应路径抑制剂
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2020181247A1 (en) * 2019-03-06 2020-09-10 Denali Therapeutics Inc. Compounds, compositions and methods
EP3959198A1 (en) * 2019-04-23 2022-03-02 Evotec International GmbH Modulators of the integrated stress response pathway

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209460A (zh) * 2013-03-14 2015-12-30 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
CN109641853A (zh) * 2016-05-05 2019-04-16 卡里科生命科学有限责任公司 整合应激通路的调节剂
CN109563071A (zh) * 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 作为atf4途径抑制剂的化学化合物
WO2019046779A1 (en) * 2017-09-01 2019-03-07 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陶天琪;刘秀华;: "内质网整合应激反应", 生理科学进展 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109736A1 (zh) * 2022-11-21 2024-05-30 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其合成方法和用途
US12612392B2 (en) 2022-11-21 2026-04-28 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical compositions containing same, synthesis method therefor and use thereof

Also Published As

Publication number Publication date
MX2021012904A (es) 2022-01-18
BR112021020106A2 (pt) 2021-12-07
IL287378A (en) 2021-12-01
EA202192900A1 (ru) 2022-03-18
WO2020216764A1 (en) 2020-10-29
AU2020262153A1 (en) 2021-11-11
IL287378B1 (en) 2025-07-01
JP7588089B2 (ja) 2024-11-21
US20220213078A1 (en) 2022-07-07
JP2022530051A (ja) 2022-06-27
IL287378B2 (en) 2025-11-01
AU2020262153B2 (en) 2026-01-22
SG11202111362SA (en) 2021-11-29
CA3137212A1 (en) 2020-10-29
EP3959210A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
CN114008041A (zh) 整合应激反应路径的调节剂
JP7699595B2 (ja) 統合的ストレス応答経路の調節因子
CN113993850A (zh) 整合应激反应途径的调节剂
JP7093306B2 (ja) ＰＤＥ１阻害剤としての１，５－ジヒドロ－４Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－４－オン及び１，５－ジヒドロ－４Ｈ－ピラゾロ［４，３－ｃ］ピリジン－４－オン
HK1210608A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
CN107531714A (zh) 作为pde1抑制剂的咪唑并吡嗪酮
CN115190813B (zh) 整合应激反应途径的调节剂
JP2023546224A (ja) 統合ストレス応答経路のモジュレーター
JP2023546226A (ja) 統合ストレス応答経路のモジュレーター
CN116964047B (zh) 整合应激反应途径的调节剂
HK40068816A (en) Modulators of the integrated stress response pathway
JP7851926B2 (ja) 統合ストレス応答経路のモジュレーター
HK40079271A (en) Modulators of the integrated stress response pathway
HK40073491A (en) Modulators of the integrated stress response pathway
HK40079271B (zh) 整合应激反应途径的调节剂
HK40100236A (zh) 整合应激反应途径的调节剂
EA048763B1 (ru) Модулятор пути интегрированного ответа на стресс и его применение
EA051483B1 (ru) Модуляторы пути интегрированного ответа на стресс
HK40068295A (en) Modulators of the integrated stress response pathway
CN116761803A (zh) 整合应激反应途径的调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068816

Country of ref document: HK